Skip to main content
Journal cover image

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Publication ,  Journal Article
Borate, U; Absher, D; Erba, HP; Pasche, B
Published in: Expert Rev Anticancer Ther
October 2012

In spite of recent advances in molecular diagnostic techniques and expanded indications for allogeneic hematopoietic stem cell transplantation, treatment of acute myeloid leukemia (AML) remains a major challenge. In the last decade, several recurrent genetic abnormalities and gene mutations with prognostic implications have been identified. This has led to improved informed treatment decisions. However, there has been limited change in the use of nonspecific cytotoxic chemotherapy and mortality rates continue to be unacceptably high, with 5 year overall survival rates of older AML patients at 30% or less. Whole-genome sequencing offers hope for greater diagnostic accuracy and is likely to lead to further characterization of disease subsets with differential outcome and response to treatment. The holy grail of personalized targeted therapy for the individual AML patient, while minimizing toxicity and prolonging survival, appears closer than ever.

Duke Scholars

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

October 2012

Volume

12

Issue

10

Start / End Page

1289 / 1297

Location

England

Related Subject Headings

  • Sequence Analysis, DNA
  • Risk Factors
  • Precision Medicine
  • Pathology, Molecular
  • Oncology & Carcinogenesis
  • Leukemia, Myeloid, Acute
  • Humans
  • Genome-Wide Association Study
  • Genome, Human
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Borate, U., Absher, D., Erba, H. P., & Pasche, B. (2012). Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. Expert Rev Anticancer Ther, 12(10), 1289–1297. https://doi.org/10.1586/era.12.116
Borate, Uma, Devin Absher, Harry P. Erba, and Boris Pasche. “Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.Expert Rev Anticancer Ther 12, no. 10 (October 2012): 1289–97. https://doi.org/10.1586/era.12.116.
Borate U, Absher D, Erba HP, Pasche B. Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. Expert Rev Anticancer Ther. 2012 Oct;12(10):1289–97.
Borate, Uma, et al. “Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.Expert Rev Anticancer Ther, vol. 12, no. 10, Oct. 2012, pp. 1289–97. Pubmed, doi:10.1586/era.12.116.
Borate U, Absher D, Erba HP, Pasche B. Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. Expert Rev Anticancer Ther. 2012 Oct;12(10):1289–1297.
Journal cover image

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

October 2012

Volume

12

Issue

10

Start / End Page

1289 / 1297

Location

England

Related Subject Headings

  • Sequence Analysis, DNA
  • Risk Factors
  • Precision Medicine
  • Pathology, Molecular
  • Oncology & Carcinogenesis
  • Leukemia, Myeloid, Acute
  • Humans
  • Genome-Wide Association Study
  • Genome, Human
  • Female